Síndrome hemolítico-urémico asociado al uso de gemcitabina: Caso clínico / Hemolytic-uremic syndrome associated with gemcitabine use: Report of one case
Rev. méd. Chile
;
141(6): 797-802, jun. 2013. ilus
Article
in Spanish
| LILACS
| ID: lil-687212
ABSTRACT
Gemcitabine is a widely used drug in the treatment of advanced pancreatic cancer and other malignancies. It is generally well tolerated and exceptionally its use has been associated with hemolytic-uremic syndrome, causing acute kidney injury, hipertension, chronic renal failure requiring dialysis, and death. We report a 60-year-old man with pancreatic carcinoma and regional lymph node invasion, whom after four months of therapy with gemcitabine and after dose number 11, suddenly developed an acute nephritic syndrome with moderate renal impairment, associated with severe anemia (hemoglobin 6.0 g/dL) and thrombocytopenia (20,000 mm³). Renal biopsy showed the classic findings of thrombotic micro angiopathy Gemcitabine was discontinued and renal function and hematological parameters gradually improved.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Deoxycytidine
/
Hemolytic-Uremic Syndrome
/
Antimetabolites, Antineoplastic
Type of study:
Risk factors
Limits:
Humans
/
Male
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2013
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Hospital Dr. Gustavo Fricke/CL
Similar
MEDLINE
...
LILACS
LIS